1. Home
  2. BCAB vs FOSL Comparison

BCAB vs FOSL Comparison

Compare BCAB & FOSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • FOSL
  • Stock Information
  • Founded
  • BCAB 2007
  • FOSL 1984
  • Country
  • BCAB United States
  • FOSL United States
  • Employees
  • BCAB N/A
  • FOSL N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • FOSL Consumer Specialties
  • Sector
  • BCAB Health Care
  • FOSL Consumer Discretionary
  • Exchange
  • BCAB Nasdaq
  • FOSL Nasdaq
  • Market Cap
  • BCAB 96.2M
  • FOSL 55.3M
  • IPO Year
  • BCAB 2020
  • FOSL 1993
  • Fundamental
  • Price
  • BCAB $2.08
  • FOSL $1.22
  • Analyst Decision
  • BCAB Strong Buy
  • FOSL
  • Analyst Count
  • BCAB 2
  • FOSL 0
  • Target Price
  • BCAB $6.00
  • FOSL N/A
  • AVG Volume (30 Days)
  • BCAB 1.6M
  • FOSL 196.4K
  • Earning Date
  • BCAB 11-08-2024
  • FOSL 11-07-2024
  • Dividend Yield
  • BCAB N/A
  • FOSL N/A
  • EPS Growth
  • BCAB N/A
  • FOSL N/A
  • EPS
  • BCAB N/A
  • FOSL N/A
  • Revenue
  • BCAB N/A
  • FOSL $1,280,256,000.00
  • Revenue This Year
  • BCAB N/A
  • FOSL N/A
  • Revenue Next Year
  • BCAB N/A
  • FOSL N/A
  • P/E Ratio
  • BCAB N/A
  • FOSL N/A
  • Revenue Growth
  • BCAB N/A
  • FOSL N/A
  • 52 Week Low
  • BCAB $1.14
  • FOSL $0.75
  • 52 Week High
  • BCAB $4.02
  • FOSL $1.83
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 55.80
  • FOSL 50.18
  • Support Level
  • BCAB $1.87
  • FOSL $1.13
  • Resistance Level
  • BCAB $2.13
  • FOSL $1.19
  • Average True Range (ATR)
  • BCAB 0.12
  • FOSL 0.05
  • MACD
  • BCAB 0.00
  • FOSL -0.01
  • Stochastic Oscillator
  • BCAB 68.90
  • FOSL 40.00

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About FOSL Fossil Group Inc.

Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.

Share on Social Networks: